In a 74-year-old bedridden woman with a prior history of deep vein thrombosis treated with apixaban (Eliquis) for 7 months and chronic residual thrombosis, and a current duplex ultrasound showing no acute DVT, should anticoagulation be restarted?

Restart Prophylactic-Dose Anticoagulation for This Bedridden Patient

Given this 74-year-old bedridden woman with prior DVT history and chronic immobility, you should restart anticoagulation with prophylactic-dose therapy—specifically apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily—to prevent recurrent VTE. Her persistent immobility represents an ongoing, non-transient risk factor that justifies extended secondary prophylaxis despite the absence of acute DVT on current imaging.

Clinical Reasoning

Why Anticoagulation is Indicated

Your patient has unprovoked DVT history (the initial episode was not clearly associated with a major transient risk factor) combined with a persistent, high-risk situation: complete immobility. This creates a clinical scenario where:

• Immobility is a well-established, ongoing VTE risk factor that doesn't resolve when the patient remains bedridden 1
• The chronic DVT finding earlier this year indicates she has residual thrombotic burden, which increases recurrence risk 2-3 fold 2
• Annual recurrence risk for unprovoked VTE exceeds 5-10% without anticoagulation 1, and immobility substantially amplifies this risk
• The current negative duplex doesn't eliminate risk—it simply means no acute clot is present now

Duration and Intensity Considerations

The key distinction here is between treatment-phase and extended-phase (secondary prophylaxis) anticoagulation:

1. She doesn't need full therapeutic dosing since there's no acute DVT currently 3, 4

2. She does need extended prophylaxis because:

   • Her immobility represents a persistent (not transient) risk factor 3, 4
   • Patients with unprovoked VTE and persistent risk factors should receive extended anticoagulation 3, 4
   • The 2021 CHEST guidelines specifically recommend offering extended-phase anticoagulation for unprovoked VTE or VTE provoked by persistent risk factors 3, 4

Specific Dosing Recommendations

Reduced-dose DOACs are the preferred option for extended secondary prophylaxis:

• Apixaban 2.5 mg twice daily 3, 5, 6
• Rivaroxaban 10 mg once daily 3, 7

These reduced doses are specifically FDA-approved for "reduction in the risk of recurrence of DVT and PE" after at least 6 months of treatment 5. The 2021 CHEST guidelines suggest reduced-dose DOACs over full-dose for extended-phase therapy, as they provide substantial VTE risk reduction with lower bleeding risk 3.

Why Not Other Options?

Against no anticoagulation:

• Her immobility is not a "transient" risk factor—it's ongoing 3, 4
• The chronic DVT finding and residual thrombus history increase her baseline recurrence risk 2
• Recurrence rates without anticoagulation would be unacceptably high (>5-10% annually) 1

Against full therapeutic dosing:

• No acute DVT present, so treatment-phase dosing (apixaban 10 mg BID initially, then 5 mg BID) is not indicated 5
• Higher bleeding risk without additional efficacy benefit in the prophylactic setting 3

Against aspirin alone:

• Aspirin provides only 30-35% risk reduction compared to 90% with anticoagulation 8
• Guidelines recommend aspirin only when patients refuse or cannot tolerate anticoagulation 3

Against mechanical prophylaxis alone:

• While compression stockings may help prevent post-thrombotic syndrome, they don't adequately prevent recurrent VTE in high-risk patients 9
• Bedridden patients often have poor compliance with mechanical devices

Practical Implementation

Starting the Medication

1. Choose apixaban 2.5 mg twice daily OR rivaroxaban 10 mg once daily

   • Apixaban may be preferable if renal function is borderline (avoid if CrCl <25 mL/min) 10, 5
   • Consider drug interactions: avoid apixaban with combined P-gp and strong CYP3A4 inhibitors 5

2. Assess bleeding risk before starting:

   • Low bleeding risk factors: age <70, no prior bleeding on anticoagulation, no concurrent antiplatelet agents 1
   • Your patient is 74, which increases bleeding risk modestly, but immobility-related VTE risk likely outweighs this 1

3. No bridging or lead-in required since this is prophylactic dosing for secondary prevention, not acute treatment 5

Monitoring and Reassessment

• Reassess at least annually for continued need, bleeding risk changes, and patient preferences 3, 4
• Monitor renal function periodically (apixaban is 27% renally cleared; adjust if CrCl declines) 10
• No routine INR or anti-Xa monitoring needed with DOACs 5
• If mobility improves significantly, consider stopping anticoagulation after shared decision-making discussion

Key Caveats

Contraindications to watch for:

• Active bleeding or high bleeding risk (recent GI bleed, intracranial hemorrhage risk)
• Severe renal impairment (CrCl <15-25 mL/min for apixaban) 10, 5
• Severe hepatic impairment 10, 5
• Concurrent use of strong dual P-gp/CYP3A4 inhibitors (ketoconazole, ritonavir) 5

If she cannot take oral medications:

• Consider LMWH (enoxaparin 40 mg SC daily) as prophylactic alternative 10
• UFH 5000 units SC every 8-12 hours is another option 10

The Bottom Line

This bedridden patient needs extended anticoagulation prophylaxis, not just observation. Her immobility is an ongoing VTE risk that won't resolve, and her history of DVT (including chronic changes) places her at high recurrence risk. Reduced-dose apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily provides optimal risk-benefit balance for long-term secondary prevention in this setting 3, 4, 6. This should continue indefinitely as long as she remains immobile and bleeding risk remains acceptable, with at least annual reassessment 3, 4.